Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol

Authors

Edurne Arriola (ORCID: https://orcid.org/0000-0001-8960-7519)
Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5376-5109)
Toon van der Gronde (ORCID: https://orcid.org/0000-0002-8688-8180)
Nir Peled (ORCID: https://orcid.org/0000-0003-3714-4377)
Heather A. Wakelee (ORCID: https://orcid.org/0000-0003-1136-980X)
Jacqueline V. Aredo (ORCID: https://orcid.org/0000-0003-0559-3565)
F. Nasirova
Ming Chen (ORCID: https://orcid.org/0000-0003-2570-0858)
Margriet Kwint
Rosemary Taylor

Institutions

AstraZeneca (United Kingdom) (GB)
Sun Yat-sen University (CN)
Shaare Zedek Medical Center (IL)
Samsung Medical Center (KR)
AstraZeneca (Brazil) (BR)
Hospital Del Mar (ES)
Sun Yat-sen University Cancer Center (CN)
Centro de Investigación Biomédica en Red de Cáncer (ES)
Stanford Cancer Institute
Sungkyunkwan University (KR)
Stanford University (US)

Publication Details

Journal: Future Oncology
Published: 2025-11-14
DOI: https://doi.org/10.1080/14796694.2025.2587569
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol

Edurne Arriola, Myung‐Ju Ahn, Toon van der Gronde, Nir Peled et al.

Nov 14, 2025

Future Oncology

Lung Cancer Treatments and Mutations

article

Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol

Edurne Arriola, Myung‐Ju Ahn, Toon van der Gronde, Nir Peled, Heather A. Wakelee, Jacqueline V. Aredo, F. Nasirova, Ming Chen, Margriet Kwint, Rosemary Taylor

November 14, 2025article en

Abstract

No abstract available for this paper.

Future OncologyVol. 21(29)

AstraZeneca (United Kingdom) (GB), Sun Yat-sen University (CN), Shaare Zedek Medical Center (IL), Samsung Medical Center (KR), AstraZeneca (Brazil) (BR), Hospital Del Mar (ES), Sun Yat-sen University Cancer Center (CN), Centro de Investigación Biomédica en Red de Cáncer (ES), Stanford Cancer Institute, Sungkyunkwan University (KR), Stanford University (US)

Openalex Percentile: Top 50%

Lung Cancer Treatments and Mutations

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.